Correction: Tamsulosin-Induced Gynecomastia: Reversible Adverse Effect - Summary - MDSpire

Reassessment: Gynecomastia as a Reversible Side Effect of Tamsulosin

August 18, 2026

Annals Of Internal Medicine: Clinical Cases

Share

Objective:

To correct the classification of tamsulosin and address its side effects, specifically gynecomastia.

Approach:

Correction of Misclassification: The article clarifies that tamsulosin is an α1-adrenergic receptor antagonist, not a 5α-reductase inhibitor.

Key Findings:

Tamsulosin is misclassified in previous literature.
Gynecomastia is identified as a reversible side effect of tamsulosin.

Limitations:

No citations or external validation of findings are provided.

Sources:

Creative Commons License

Original Source(s)

Annals Of Internal Medicine: Clinical Cases

Correction: Tamsulosin-Induced Gynecomastia: Reversible Adverse Effect

August 18, 2026

Related Content

Jama Network Open

National Cancer Institute–Supported Obesity and Cancer Research, 2015-2022

Kff Health News

How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages

“There is incredible uncertainty in drug dosing.”

by Arthur Allen
August 20, 2026
15 min

United States Department Of Health And Human Services

HHS Ends Federal Medicaid and CHIP Funding for Sex-Rejecting Procedures for Children and Youth

by Assistant Secretary for Public Affairs (ASPA)
August 11, 2026